About
Echosens is a medical technology company focused on non-invasive liver health diagnostics, renowned for its flagship product, FibroScan®. Founded in 2001, Echosens has established itself as a leader in liver disease assessment, utilizing innovative technologies developed from research in Paris. The company's core technology, controlled vibration transient elastography (VCTE™), allows for accurate measurement of liver stiffness, essential for diagnosing chronic liver diseases. Echosens also offers the Controlled Attenuation Parameter (CAP™) technology to evaluate liver fat accumulation, providing a comprehensive assessment of liver health. Their product portfolio includes various FibroScan® models, such as the FibroScan® 502, Mini+ 430, Compact 530, and GO, catering to different clinical needs and settings. Echosens serves healthcare professionals, hepatologists, and pharmaceutical companies in over 100 countries, supported by extensive clinical research. With a commitment to innovation, the company invests significantly in product development and holds numerous international patents, aiming to enhance liver disease diagnosis and patient care.
Technologies
Keywords
Company Information
-
Employees 350
-
Founded 2001
-
Annual Revenue $104200000
-
Total Funding $33000000
Location
6 Rue Ferrus, Paris, Ile-de-France, France, 75014